Comparative Pharmacology
Head-to-head clinical analysis: MERILOG SOLOSTAR versus NOVOLIN R.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MERILOG SOLOSTAR versus NOVOLIN R.
MERILOG SOLOSTAR vs NOVOLIN R
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin glargine is a recombinant human insulin analog that exhibits prolonged duration of action due to slow subcutaneous absorption. It binds to insulin receptors, activating downstream signaling pathways involved in glucose uptake, glycogen synthesis, and lipogenesis.
Regular insulin lowers blood glucose by promoting peripheral glucose uptake, especially in skeletal muscle and adipose tissue, and by inhibiting hepatic glucose production. It binds to insulin receptors on cell membranes, activating tyrosine kinase activity and downstream signaling pathways that regulate glucose transport and metabolism.
0.5 mg subcutaneously once a day.
Subcutaneous: 0.5-1 unit/kg/day divided into 2-3 doses; intravenous: continuous infusion starting at 0.05-0.1 units/kg/hr adjusted based on blood glucose.
None Documented
None Documented
Terminal half-life is about 24 hours (range 18–30 hours), allowing once-daily dosing.
Intravenous: 5-10 minutes (short due to rapid distribution and degradation). Subcutaneous: 1-2 hours (terminal half-life after absorption).
Approximately 80% of the dose is excreted renally as unchanged drug, with 20% eliminated via bile/feces.
Renal (tubular reabsorption and metabolism). Approximately 50-80% of insulin is degraded in the liver and kidneys; the remainder is excreted in urine as metabolites and intact hormone (<1%).
Category C
Category C
Insulin
Insulin